Abstract
Background As reported by Iranian governments, the first cases of coronavirus (COVID-19) infections confirmed in Qom, Iran on February 19, 2020 (30 Bahman 1398). The number of identified cases afterward increased rapidly and the novel coronavirus spread to all provinces of the country. This study aimed to fit an epidemic model to the reported cases data to estimate the basic reproduction number (R0) of COVID-19 in Iran.
Methods We used data from February 21, 2020, to April 21, 2020, on the number of cases reported by Iranian governments and we employed the SIR (Susceptible-Infectious-Removed) epidemic spreading model to fit the transmission model to the reported cases data by tuning the parameters in order to estimate the basic reproduction number of COVID-19 in Iran.
Results The value of reproduction number was estimated 4.86 in the first week and 4.5 in the second week. it decreased from 4.29 to 2.37 in the next four weeks. At the seventh week of the outbreak the reproduction number was reduced below one.
Conclusions The results indicate that the basic reproduction number of COVID-19 was significantly larger than one in the early stages of the outbreak. However, implementing social distancing and preventing travelling on Nowruz (Persian New Year) effectively reduced the reproduction number. Although the results indicate that reproduction number is below one, it is necessary to continue social distancing and control travelling to prevent causing a second wave of outbreak.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors received no specific funding for this work.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Information related to the study is in the manuscript
